Conestoga Capital Advisors LLC Sells 6,300 Shares of Vericel Co. (NASDAQ:VCEL)

Conestoga Capital Advisors LLC made a late Q4 transaction in Vericel Co. (NASDAQ:VCEL) shares decreasing its stake by 0.3%. The most recent Form 13F filed with the SEC discloses that the fund sold 6,300 shares and owned 2,069,430 shares of the biotechnology company as of the end of the quarter. The largest stake in Vericel was that of Conestoga Capital Advisors LLC, which held 4.19% of the company's shares, worth $113,632,000 as of the most recent filing with the Securities and Exchange Commission.
Other institutional investors also in their portfolio have recently altered the holdings of the company. International Assets Investment Management LLC has increased its stake in Vericel by 4,126.7% during the third quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 619 shares in the last quarter. Farther Finance Advisors LLC has boosted its holdings in Vericel by 48.1% in the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company's stock, or $53,000, after purchasing an additional 405 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. has increased its stake in the shares of Vericel by 22.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. owns 1,773 shares of the biotechnology company's stock, or $77,000, after purchasing an additional 322 shares in the last quarter. Meeder Asset Management Inc. has bought a new position in the company's shares in the third quarter with a market value of $92,000. Geneos Wealth Management Inc. has increased its position in Vericel by 826.6% during the 4th quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company's stock, or $138,000, after buying 2,240 shares in the last quarter.
NASDAQ VCEL started trading on Monday at $58.54. The company's 50-day moving average is $57.69, and its 200-day moving average is $50.86. Vericel Co. has a one year low of $39.12 and a one year high of $61.99. The firm has a market cap of $2.89 billion, a P/E ratio of 975.83 and a beta of 1.72.
Vericel (NASDAQ:VCEL) last announced its quarterly results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, which was better than the consensus estimate by ($0.05). Net profit margin of Vericel was 1.56%; return on equity stood at 1.48%. The company’s revenue of $57.91 million in the quarter was better than the consensus estimate of $55.32 million. The analysts expect Vericel to post earnings of 0.14 per share for the fiscal year.
The shares of VCEL were covered by a number of analysts. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating on Tuesday, December 24. Canaccord Genuity Group has upgraded Vericel to buy and raised its price target to $64.00 from $58.00. Stephens has made a rating of overweight and has set a price target on Vericel of $65.00 in a report on Wednesday, January 15. BTIG Research upgraded its price target on shares of Vericel to $66.00 from $56.00 and gave the company a buy rating on Tuesday, November 26. Finally, Truist Financial has raised the price target for shares of Vericel to $67.00 from $61.00 and has kept the rating as buy in a report on Wednesday, December 18. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Vericel has received an average rating of Moderate Buy and its average target price is $63.14.
First, get the big picture: MarketBeat tracks Wall Street's top-rated and most successful analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified these five stocks that top analysts think are best bought now before the rest of the market realizes it, and Vericel wasn’t one of them.
Before making any decisions regarding Vericel, you should read our latest analysis.

Shandor Brenner is an American journalist recognized for his sharp and insightful reporting on social and political issues. His work is known for its depth, integrity, and the ability to highlight critical societal concerns.